Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.24.1.u1
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
 3 Months Ended
Oct. 30, 2023
USD ($)
Mar. 22, 2021
USD ($)
item
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs     $ 15,000 $ 9,600  
Short-term royalty and commercial payment receivables     9,819   $ 14,215
Viracta | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item   2      
Payments of consideration under RPAs, AAAs and CPPAs   $ 13,500      
Maximum amount of potential milestones, potential royalties on sales and other payments receivable   54,000      
Amount of maximum consideration retained   5,000      
Maximum amount of potential regulatory and commercial milestones receivable   57,000      
Acquisition of royalty and commercial payment receivables, Long-Term   $ 13,500      
Amount of milestone payments earned under agreement $ 5,000        
Reduction in long-term royalty receivable balance due to receipt of payment $ 5,000        
Amount of allowance for credit losses     $ 0   $ 0